Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

Karim Fizazi, Johann S. de Bono, Christopher J. Logothetis et al.|The Lancet Oncology|2012

Cited by 1.4k